InterMune Ad Improperly Infers Infergen Superiority, FDA’s Ad Division Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A DDMAC untitled letter accuses InterMune of overstating efficacy and omitting safety information in an ad for chronic hepatitis C therapy Infergen.
You may also be interested in...
InterMune Phase III Efforts Will Be Funded Through Infergen Sale
Proceeds from InterMune’s sale of the hepatitis C agent to Valeant will be used for development of idiopathic pulmonary fibrosis therapies.
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says
Mail-Order Pharmacy Not Necessarily Cheaper To Health Plans, Ohio Finds
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago